ALPACCA
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- NCT07185997 ↗
- Recruiting
- ArriVent BioPharma, Inc.
- Deep
We haven't built an HCP commentary report on ALPACCA (firmonertinib in Non-Small-Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ALPACCA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 17 | |
| YouTube | 3 | |
| Podcasts | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer; EGFR P-Loop and Alpha C-Helix Compressing; EGFR PACC; EGFR Uncommon Mutations
- Interventions
- Firmonertinib; EGFR-TKI inhibitor based on investigator's choice
- Arms
- Firmonertinib 240 mg · Experimental
- EGFR-TKI inhibitor osimertinib or afatinib based on investigator's choice · Active comparator
- Enrollment
- 480 (estimated)
- Primary outcomes
- Progression Free Survival (PFS) determined by blinded independent central review (BICR)
- Confirmed overall response rate (ORR) as determined by BICR
- Sponsor
- ArriVent BioPharma, Inc.
- Start
- Dec 17, 2025
- Primary completion
- Feb 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07185997 · updated Oct 14, 2026